ProCE Banner Activity

影响我在 CROI 2022 之后的实践的关键 HIV 研究

Slideset Download
Conference Coverage
阅读专家科研人员对来自 CROI 2022 的关键 HIV 研究的总结,包括预防策略、长效疗法、二线疗法、合并症和治愈的研究结果。

Released: March 21, 2022

Expiration: March 20, 2023

Share

Faculty

Monica Gandhi

Monica Gandhi, MD, MPH

Professor of Medicine
Associate Chief, Division of HIV, Infectious Diseases and Global Medicine
Director, Center for AIDS Research
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco 
San Francisco, California

Daniel R. Kuritzkes

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

David A. Wohl

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

由 Gilead Sciences, Inc. 提供的教育补助金 支持。 Janssen Therapeutics,Janssen Products, LP 的事业部 Merck & Co., Inc. ViiV Healthcare

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Monica Gandhi, MD, MPH

Professor of Medicine
Associate Chief, Division of HIV, Infectious Diseases and Global Medicine
Director, Center for AIDS Research
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco 
San Francisco, California

医学博士和公共卫生学硕士 Monica Gandhi, 没有相关的利益冲突要报告。

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

医学博士 Daniel R. Kuritzkes 在报告中表示,他获得了 Gilead Sciences、Merck 和 ViiV Healthcare 提供的研究资助金,以及 Abpro、Atea、Decoy、Gilead Sciences、GlaxoSmithKline、Janssen、Merck、ViiV Healthcare 和 ViroStatics 提供的咨询费。

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo,MBBS,已透露,他已收到 Gilead Sciences、Merck 和 ViiV Healthcare/GSK 的咨询费,以及 Johnson & Johnson 为独立承包商提供的资金。

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

医学博士 David A. Wohl 透露,它已收到 Gilead Sciences 和 Merck 的研究支持资金,以及 Gilead Sciences、Janssen、Merck 和 ViiV 的咨询费。